Entrada Therapeutics, Inc. financial data

Symbol
TRDA on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Design Center Place, Suite 17 500, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CycloPorters, Inc. (to 11/10/2016)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 250 % -53.9%
Debt-to-equity 103 % +162%
Return On Equity 9.73 %
Return On Assets 4.8 %
Operating Margin 14.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.6 M shares +1.22%
Common Stock, Shares, Outstanding 33.6 M shares +1.42%
Entity Public Float 431 M USD +57.1%
Common Stock, Value, Issued 3 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.5 M shares +3.47%
Weighted Average Number of Shares Outstanding, Diluted 34.8 M shares +7.47%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 163 M USD +134%
Research and Development Expense 105 M USD +42.4%
General and Administrative Expense 33.8 M USD +5%
Operating Income (Loss) 23.7 M USD
Income Tax Expense (Benefit) 17 M USD +379%
Net Income (Loss) Attributable to Parent 23.5 M USD
Earnings Per Share, Basic 0.71 USD/shares
Earnings Per Share, Diluted 0.69 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.4 M USD -69.9%
Marketable Securities, Current 162 M USD
Cash, Cash Equivalents, and Short-term Investments 327 M USD -20.5%
Assets, Current 414 M USD -4.6%
Property, Plant and Equipment, Net 11 M USD +17.1%
Operating Lease, Right-of-Use Asset 79 M USD +454%
Other Assets, Noncurrent 2.76 M USD -80%
Assets 511 M USD +7.42%
Accounts Payable, Current 2.53 M USD -61%
Employee-related Liabilities, Current 3.04 M USD +48.3%
Accrued Liabilities, Current 8.79 M USD -24.7%
Liabilities, Current 174 M USD +17.8%
Operating Lease, Liability, Noncurrent 58.1 M USD +537%
Liabilities 241 M USD -1.82%
Accumulated Other Comprehensive Income (Loss), Net of Tax -246 K USD +61.7%
Retained Earnings (Accumulated Deficit) -171 M USD +12%
Stockholders' Equity Attributable to Parent 269 M USD +17.3%
Liabilities and Equity 511 M USD +7.42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5 M USD -113%
Net Cash Provided by (Used in) Financing Activities 206 K USD -98.9%
Net Cash Provided by (Used in) Investing Activities 26.1 M USD
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 33.6 M shares +1.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 834 K USD -99.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 72.4 M USD -68.7%
Deferred Tax Assets, Valuation Allowance 77.9 M USD +35.7%
Deferred Tax Assets, Gross 102 M USD +57.9%
Operating Lease, Liability 68.2 M USD +163%
Depreciation 3.23 M USD +58.1%
Payments to Acquire Property, Plant, and Equipment 838 K USD -49.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 23.9 M USD
Lessee, Operating Lease, Liability, to be Paid 94.6 M USD +246%
Property, Plant and Equipment, Gross 17.7 M USD +34.1%
Operating Lease, Liability, Current 8.3 M USD +16.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2 M USD +38.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.1 M USD +41.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26.4 M USD +1748%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.83 M USD +2.04%
Deferred Tax Assets, Operating Loss Carryforwards 3.62 M USD -88.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.08 M USD
Operating Lease, Payments 2.28 M USD +24.1%
Additional Paid in Capital 441 M USD +3.73%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 14.1 M USD +29.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%